Chromogranin A: A paradoxical player in angiogenesis and vascular biology

Cellular and Molecular Life Sciences

Volumn 72, Issue 2, 2015, Pages 339-348

  Helle, Karen B ^a   Corti, Angelo ^b  

^a UNIVERSITY OF BERGEN   (Norway)

^b SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Angiogenic switch; Cancer; Cardiovascular regulation; ELISA assays; Endothelial barrier; Proteolytic processing

Indexed keywords

CATESTATIN; CHROMOGRANIN A; RECEPTOR PROTEIN; UNCLASSIFIED DRUG; VASOSTATIN 1; CHROMOGRANIN A (344-364); PEPTIDE FRAGMENT; VASOSTATIN I;

AMINO TERMINAL SEQUENCE; ANGIOGENESIS; BLOOD VESSEL PERMEABILITY; CANCER GROWTH; CARBOXY TERMINAL SEQUENCE; CARDIOVASCULAR FUNCTION; HOMEOSTASIS; HUMAN; INFLAMMATION; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; TISSUE REPAIR; VASCULAR BIOLOGY; ANIMAL; BLOOD; BLOOD VESSEL; BOVINE; ENZYME LINKED IMMUNOSORBENT ASSAY; METABOLISM; MOUSE; NEOPLASM; PHYSIOLOGY; PROCEDURES;

ANIMALS; BLOOD VESSELS; CATTLE; CHROMOGRANIN A; ENZYME-LINKED IMMUNOSORBENT ASSAY; HOMEOSTASIS; HUMANS; MICE; NEOPLASMS; NEOVASCULARIZATION, PHYSIOLOGIC; PEPTIDE FRAGMENTS;

EID: 84922093619     PISSN: 1420682X     EISSN: 14209071     Source Type: Journal    
DOI: 10.1007/s00018-014-1750-9     Document Type: Review

References (70)

1. Banks P, Helle KB (1965) The release of protein from the stimulated adrenal medulla. Biochem J 97:40C-41C
2. Blaschko H, Comline RS, Schneider FH, Silver M, Smith AD (1967) Secretion of a chromaffin granule protein, chromogranin, from the adrenal gland after splanchnic stimulation. Nature 215:58-59
3. O'Connor DT, Bernstein KN (1984) Radioimmunoassay of chromogranin A in plasma as a measure of exocytotic sympathoadrenal activity in normal subjects and patients with pheochromocytoma. N Engl J Med 311:764-770
4. Iacangelo A, Affolter HU, Eiden LE, Herbert E, Grimes M (1986) Bovine chromogranin A sequence and distribution of its messenger RNA in endocrine tissues. Nature 323:82-86
5. Benedum UM, Baeuerle PA, Konecki DS, Frank R, Powell J, Mallet J, Huttner WB (1986) The primary structure of bovine chromogranin A: a representative of a class of acidic secretory proteins common to a variety of peptidergic cells. EMBO J 5:1495-1502
6. Tatemoto K, Efendic S, Mutt V, Makk G, Feistner GJ, Barchas JD (1986) Pancreastatin, a novel pancreatic peptide that inhibits insulin secretion. Nature 324:476-478
7. Eiden LE (1987) Is chromogranin a prohormone? Nature 325:301
8. Huttner WB, Benedum UM (1987) Chromogranin A and pancreastatin. Nature 325:305
9. Aardal S, Helle KB (1992) The vasoinhibitory activity of bovine chromogranin A fragment (vasostatin) and its independence of extracellular calcium in isolated segments of human blood vessels. Regul Pept 41:9-18
10. Mahata SK, O'Connor DT, Mahata M, Yoo SH, Taupenot L, Wu H, Gill BM, Parmer RJ (1997) Novel autocrine feedback control of catecholamine release. A discrete chromogranin a fragment is a noncompetitive nicotinic cholinergic antagonist. J Clin Invest 100:1623-1633
11. Helle KB, Corti A, Metz-Boutigue MH, Tota B (2007) The endocrine role for chromogranin A: a prohormone for peptides with regulatory properties. Cell Mol Life Sci 64:2863-2886
12. Corti A, Ferrero E (2012) Chromogranin A and the endothelial barrier function. Curr Med Chem 19:4051-4058
13. Crippa L, Bianco M, Colombo B, Gasparri AM, Ferrero E, Loh YP, Curnis F, Corti A (2013) A new chromogranin A-dependent angiogenic switch activated by thrombin. Blood 121:392-402
14. Helle KB (2010) The chromogranin A-derived peptides vasostatin-I and catestatin as regulatory peptides for cardiovascular functions. Cardiovasc Res 85:9-16
15. Theurl M, Schgoer W, Albrecht K, Jeschke J, Egger M, Beer AG, Vasiljevic D, Rong S, Wolf AM, Bahlmann FH et al (2010) The neuropeptide catestatin acts as a novel angiogenic cytokine via a basic fibroblast growth factor-dependent mechanism. Circ Res 107:1326-1335
16. Pasqua T, Corti A, Gentile S, Pochini L, Bianco M, Metz-Boutigue MH, Cerra MC, Tota B, Angelone T (2013) Full-length human Chromogranin-A cardioactivity: myocardial, coronary and stimulus-induced processing evidence in normotensive and hypertensive male rat hearts. Endocrinology 154(9):3353-3365
17. Ji L, Pei ZQ, Ma DF, Zhang J, Su JS, Gao XD, Xue WZ, Chen XP, Wang WS (2012) Prognostic value of circulating catestatin levels for in-hospital heart failure in patients with acute myocardial infarction. Zhonghua Xin Xue Guan Bing Za Zhi 40:914-919
18. Meng L, Wang J, Ding WH, Han P, Yang Y, Qi LT, Zhang BW (2013) Plasma catestatin level in patients with acute myocardial infarction and its correlation with ventricular remodelling. Postgrad Med J 89:193-196
19. O'Connor DT, Kailasam MT, Kennedy BP, Ziegler MG, Yanaihara N, Parmer RJ (2002) Early decline in the catecholamine release-inhibitory peptide catestatin in humans at genetic risk of hypertension. J Hypertens 20:1335-1345
20. Fournier I, Gaucher D, Chich JF, Bach C, Shooshtarizadeh P, Picaud S, Bourcier T, Speeg-Schatz C, Strub JM, Van Dorsselaer A et al (2011) Processing of chromogranins/secretogranin in patients with diabetic retinopathy. Regul Pept 167:118-124
21. Schneider F, Bach C, Chung H, Crippa L, Lavaux T, Bollaert PE, Wolff M, Corti A, Launoy A, Delabranche X et al (2012) Vasostatin-I, a chromogranin A-derived peptide, in non-selected critically ill patients: distribution, kinetics, and prognostic significance. Intensive Care Med 38:1514-1522
22. Liu L, Ding W, Zhao F, Shi L, Pang Y, Tang C (2013) Plasma levels and potential roles of catestatin in patients with coronary heart disease. Scand Cardiovasc J 47:217-224
23. Metz-Boutigue MH, Garcia-Sablone P, Hogue-Angeletti R, Aunis D (1993) Intracellular and extracellular processing of chromogranin A. Determination of cleavage sites. Eur J Biochem 217:247-257
24. Belloni D, Scabini S, Foglieni C, Veschini L, Giazzon A, Colombo B, Fulgenzi A, Helle KB, Ferrero ME, Corti A et al (2007) The vasostatin-I fragment of chromogranin A inhibits VEGF-induced endothelial cell proliferation and migration. FASEB J 21:3052-3062
25. Ferrero E, Scabini S, Magni E, Foglieni C, Belloni D, Colombo B, Curnis F, Villa A, Ferrero ME, Corti A (2004) Chromogranin A protects vessels against tumor necrosis factor alpha-induced vascular leakage. FASEB J 18(3):554-555
26. Dondossola E, Crippa L, Colombo B, Ferrero E, Corti A (2012) Chromogranin A regulates tumor self-seeding and dissemination. Cancer Res 72:449-459
27. Blois A, Srebro B, Mandalà M, Corti A, Helle KB, Serck-Hanssen G (2006) The chromogranin A peptide vasostatin-I inhibits gap formation and signal transduction mediated by inflammatory agents in cultured bovine pulmonary and coronary arterial endothelial cells. Regul Pept 135:78-84
28. Breslin JW, Pappas PJ, Cerveira JJ, Hobson RW 2nd, Duran WN (2003) VEGF increases endothelial permeability by separate signaling pathways involving ERK-1/2 and nitric oxide. Am J Physiol Heart Circ Physiol 284:H92-H100
29. Koss M, Pfeiffer GR 2nd, Wang Y, Thomas ST, Yerukhimovich M, Gaarde WA, Doerschuk CM, Wang Q (2006) Ezrin/radixin/moesin proteins are phosphorylated by TNF-alpha and modulate permeability increases in human pulmonary microvascular endothelial cells. J Immunol 176:1218-1227
30. Pieroni M, Corti A, Tota B, Curnis F, Angelone T, Colombo B, Cerra MC, Bellocci F, Crea F, Maseri A (2007) Myocardial production of chromogranin A in human heart: a new regulatory peptide of cardiac function. Eur Heart J 28:1117-1127
31. Ceconi C, Ferrari R, Bachetti T, Opasich C, Volterrani M, Colombo B, Parrinello G, Corti A (2002) Chromogranin A in heart failure; a novel neurohumoral factor and a predictor for mortality. Eur Heart J 23:967-974
32. Goetze JP, Hilsted LM, Rehfeld JF, Alehagen U (2014) Plasma chromogranin A is a marker of death in elderly patients presenting with symptoms of heart failure. Endocr Connect 3:47-56
33. Jansson AM, Rosjo H, Omland T, Karlsson T, Hartford M, Flyvbjerg A, Caidahl K (2009) Prognostic value of circulating chromogranin A levels in acute coronary syndromes. Eur Heart J 30:25-32
34. Tota B, Gentile S, Pasqua T, Bassino E, Koshimizu H, Cawley NX, Cerra MC, Loh YP, Angelone T (2012) The novel chromogranin A-derived serpinin and pyroglutaminated serpinin peptides are positive cardiac beta-adrenergic-like inotropes. FASEB J 26:2888-2898
35. Angelone T, Quintieri AM, Brar BK, Limchaiyawat PT, Tota B, Mahata SK, Cerra MC (2008) The antihypertensive chromogranin a peptide catestatin acts as a novel endocrine/paracrine modulator of cardiac inotropism and lusitropism. Endocrinology 149:4780-4793
36. Cerra MC, De Iuri L, Angelone T, Corti A, Tota B (2006) Recombinant N-terminal fragments of chromogranin-A modulate cardiac function of the Langendorff-perfused rat heart. Basic Res Cardiol 101:43-52
37. Loh YP, Cheng Y, Mahata SK, Corti A, Tota B (2012) Chromogranin A and derived peptides in health and disease. J Mol Neurosci 48:347-356
38. Corti A, Ferrari R, Ceconi C (2000) Chromogranin A and tumor necrosis factor-alpha (TNF) in chronic heart failure. Adv Exp Med Biol 482:351-359
39. Ben-Haim S, Gacinovic S, Israel O (2009) Cardiovascular infection and inflammation. Semin Nucl Med 39:103-114
40. Tatasciore A, Zimarino M, Renda G, Zurro M, Soccio M, Prontera C, Emdin M, Flacco M, Schillaci G, De Caterina R (2008) Awake blood pressure variability, inflammatory markers and target organ damage in newly diagnosed hypertension. Hypertens Res 31:2137-2146
41. Anaya-Prado R, Toledo-Pereyra LH (2002) The molecular events underlying ischemia/reperfusion injury. Transplant Proc 34:2518-2519
42. Rodriguez-Sinovas A, Abdallah Y, Piper HM, Garcia-Dorado D (2007) Reperfusion injury as a therapeutic challenge in patients with acute myocardial infarction. Heart Fail Rev 12:207-216
43. Cappello S, Angelone T, Tota B, Pagliaro P, Penna C, Rastaldo R, Corti A, Losano G, Cerra MC (2007) Human recombinant chromogranin A-derived vasostatin-1 mimics preconditioning via an adenosine/nitric oxide signaling mechanism. Am J Physiol Heart Circul Physiol 293:H719-H727
44. Penna C, Tullio F, Perrelli MG, Mancardi D, Pagliaro P (2012) Cardioprotection against ischemia/reperfusion injury and chromogranin A-derived peptides. Curr Med Chem 19:4074-4085
45. Cappello S, Angelone T, Tota B, Pagliaro P, Penna C, Rastaldo R, Corti A, Losano G, Cerra MC (2007) Human recombinant chromogranin A-derived vasostatin-1 mimics preconditioning via an adenosine/nitric oxide signaling mechanism. Am J Physiol Heart Circ Physiol 293:H719-H727
46. Penna C, Alloatti G, Gallo MP, Cerra MC, Levi R, Tullio F, Bassino E, Dolgetta S, Mahata SK, Tota B et al (2010) Catestatin improves post-ischemic left ventricular function and decreases ischemia/reperfusion injury in heart. Cell Mol Neurobiol 30:1171-1179
47. Brar BK, Helgeland E, Mahata SK, Zhang K, O'Connor DT, Helle KB, Jonassen AK (2010) Human catestatin peptides differentially regulate infarct size in the ischemic-reperfused rat heart. Regul Pept 165:63-70
48. Glattard E, Angelone T, Strub JM, Corti A, Aunis D, Tota B, Metz-Boutigue MH, Goumon Y (2006) Characterization of natural vasostatin-containing peptides in rat heart. FEBS J 273:3311-3321
49. Biswas N, Curello E, O'Connor DT, Mahata SK (2010) Chromogranin/secretogranin proteins in murine heart: myocardial production of chromogranin A fragment catestatin (Chga(364-384)). Cell Tissue Res 342:353-361
50. Foster W, Carruthers D, Lip GY, Blann AD (2009) Relationships between endothelial, inflammatory and angiogenesis markers in rheumatoid arthritis: implications for cardiovascular pathophysiology. Thromb Res 123:659-664
51. Capellino S, Lowin T, Angele P, Falk W, Grifka J, Straub RH (2008) Increased chromogranin A levels indicate sympathetic hyperactivity in patients with rheumatoid arthritis and systemic lupus erythematosus. J Rheumatol 35:91-99
52. Di Comite G, Rossi CM, Marinosci A, Lolmede K, Baldissera E, Aiello P, Mueller RB, Herrmann M, Voll RE, Rovere-Querini P et al (2009) Circulating chromogranin A reveals extra-articular involvement in patients with rheumatoid arthritis and curbs TNF-alpha-elicited endothelial activation. J Leukoc Biol 85:81-87
53. Portela-Gomes GM, Grimelius L, Wilander E, Stridsberg M (2010) Granins and granin-related peptides in neuroendocrine tumours. Regul Pept 165:12-20
54. Taupenot L, Harper KL, O'Connor DT (2003) The chromogranin-secretogranin family. N Engl J Med 348:1134-1149
55. Guerin M, Guillemot J, Thouennon E, Pierre A, El-Yamani FZ, Montero-Hadjadje M, Dubessy C, Magoul R, Lihrmann I, Anouar Y et al (2010) Granins and their derived peptides in normal and tumoral chromaffin tissue: implications for the diagnosis and prognosis of pheochromocytoma. Regul Pept 165:21-29
56. Corti A (2010) Chromogranin A and the tumor microenvironment. Cell Mol Neurobiol 30:1163-1170
57. Stridsberg M, Eriksson B, Oberg K, Janson ET (2003) A comparison between three commercial kits for chromogranin A measurements. J Endocrinol 177:337-341
58. Colombo B, Curnis F, Foglieni C, Monno A, Arrigoni G, Corti A (2002) Chromogranin a expression in neoplastic cells affects tumor growth and morphogenesis in mouse models. Cancer Res 62:941-946
59. Mandala M, Stridsberg M, Helle KB, Serck-Hanssen G (2000) Endothelial handling of chromogranin A. Adv Exp Med Biol 482:167-178
60. Angeletti RH, Aardal S, Serck-Hanssen G, Gee P, Helle KB (1994) Vasoinhibitory activity of synthetic peptides from the amino terminus of chromogranin A. Acta Physiol Scand 152:11-19
61. Russell J, Gee P, Liu SM, Angeletti RH (1994) Inhibition of parathyroid hormone secretion by amino-terminal chromogranin peptides. Endocrinology 135:337-342
62. Ramella R, Boero O, Alloatti G, Angelone T, Levi R, Gallo MP (2010) Vasostatin 1 activates eNOS in endothelial cells through a proteoglycan-dependent mechanism. J Cell Biochem 110:70-79
63. Dondossola E, Gasparri A, Bachi A, Longhi R, Metz-Boutigue MH, Tota B, Helle KB, Curnis F, Corti A (2010) Role of vasostatin-1 C-terminal region in fibroblast cell adhesion. Cell Mol Life Sci 67:2107-2118
64. Curnis F, Gasparri A, Longhi R, Colombo B, D'Alessio S, Pastorino F, Ponzoni M, Corti A (2012) Chromogranin A binds to αvβ6-integrin and promotes wound healing in mice. Cell Mol Life Sci 69:2791-2803
65. Thomas GJ, Nystrom ML, Marshall JF (2006) Alphavbeta6 integrin in wound healing and cancer of the oral cavity. J Oral Pathol Med 35:1-10
66. Busk M, Pytela R, Sheppard D (1992) Characterization of the integrin alpha v beta 6 as a fibronectin-binding protein. J Biol Chem 267:5790-5796
67. Bandyopadhyay A, Raghavan S (2009) Defining the role of integrin alphavbeta6 in cancer. Curr Drug Targets 10:645-652
68. Koivisto L, Larjava K, Hakkinen L, Uitto VJ, Heino J, Larjava H (1999) Different integrins mediate cell spreading, haptotaxis and lateral migration of HaCaT keratinocytes on fibronectin. Cell Adhes Commun 7:245-257
69. Avraamides CJ, Garmy-Susini B, Varner JA (2008) Integrins in angiogenesis and lymphangiogenesis. Nat Rev Cancer 8:604-617
70. Desgrosellier JS, Cheresh DA (2010) Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 10:9-22